Advertisements


AstraZeneca"s Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

Zacks.....»»

Category: topSource: redinewsSep 14th, 2018

AstraZeneca Receives FDA Approval For Rare B-Cell Lymphoma Drug Lumoxiti

AstraZeneca Receives FDA Approval For Rare B-Cell Lymphoma Drug Lumoxiti.....»»

Category: topSource: seekingalphaSep 18th, 2018

AstraZeneca"s Tagrisso Wins EU Nod for First-Line Lung Cancer

AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) m.....»»

Category: personnelSource: nytJun 11th, 2018

Novartis" CAR-T Therapy Kymriah Gets Approval in Europe

Novartis (NVS) gets EC approval for CAR-T therapy, Kymriah, for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia. Novartis AG NVS announced that the European Commiss.....»»

Category: worldSource: nytAug 27th, 2018

Johns Hopkins All Children"s becomes first Florida pediatric hospital to have unique leukemia therapy

Johns Hopkins All Children’s Hospital is now the first pediatric hospital in Florida offering a cutting-edge cellular immunotherapy for advanced leukemia in children and young adults. It will be offering CAR-T Cell Gene Therapy for leukemia. Chimer.....»»

Category: topSource: bizjournalsAug 30th, 2018

FDA grants approval of HCL treatment Lumoxiti to AstraZeneca

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2018

AstraZeneca says FDA approves LUMOXITI for certain patients

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2018

Roth Capital remains bullish on Stemline after AstraZeneca"s Lumoxiti approved

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 14th, 2018

AstraZeneca's Lynparza shown to put brakes on ovarian cancer - Reuters

ReutersAstraZeneca's Lynparza shown to put brakes on ovarian cancerReutersMUNICH (Reuters) - An AstraZeneca drug that blocks a cancer cell's ability to repair its g.....»»

Category: topSource: googlenewsOct 22nd, 2018

Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For the Treatment Of Peripheral T-Cell Lymphoma

BOSTON, Mass.--(BUSINESS WIRE)-- Verastem, Inc. read more.....»»

Category: blogSource: benzingaNov 7th, 2018

Cell Tower Shutdown After Complaints About Cancer-Cluster In School Kids

Via SharylAttkisson.com, A controversial cell phone tower near a school in Ripon, California has been shut down amid reports of four students and three teachers children being dia.....»»

Category: blogSource: zerohedge14 hr. 52 min. ago

Orgenesis shares soar 19% premarket after FDA grants orphan designation to insulin tech

Orgenesis Inc. shares soared 19% in premarket trade Monday, after the U.S. Food and Drug Administration granted Orphan Drug Designation to the company's Autologous Insulin Producing cells as a cell replacement therapy for the treatment of severe hypogl.....»»

Category: topSource: marketwatch17 hr. 53 min. ago

Pluristem presents its first proprietary serum-free cell therapy product

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 52 min. ago

Casi Pharmaceuticals acquires rights to commercialize anti-CD19 T-cell therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall19 hr. 52 min. ago

Bloom Energy: Is There Finally A Fuel Cell Company Worth Buying?

Bloom Energy: Is There Finally A Fuel Cell Company Worth Buying?.....»»

Category: topSource: seekingalphaJun 16th, 2019

Editas presents pre-clinical data in Sickle Cell Disease, Beta-Thalassemia

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 16th, 2019

AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 16th, 2019

The Stem Cell Triple Play: 3 Companies With Great Value Drivers

The Stem Cell Triple Play: 3 Companies With Great Value Drivers.....»»

Category: topSource: seekingalphaJun 14th, 2019

The Stem Cell Triple Play: 3 Companies WIth Great Value Drivers

The Stem Cell Triple Play: 3 Companies WIth Great Value Drivers.....»»

Category: topSource: seekingalphaJun 14th, 2019

Amgen acute myeloid leukemia treatment granted FDA orphan status

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2019

AstraZeneca says Lokelma demonstrated efficacy in Phase IIIb DIALIZE trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2019